4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-21-055171
Chief Scientific Officer sold 1,600 shares at $35.00 ($56,000)
- Chief Scientific Officer acquired 1,600 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-09-07 | Exercise or conversion : show line 1 in the form | +1,600 | $7.26 | $11,616 | 15,797 | D |
| 2021-09-07 | Sale : show line 2 in the form | −1,600 | $35.00 | $56,000 | 14,197 | D |
| Open-market sales · 1,600 sh · avg $35.00 · $56,000 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-09-07 | Exercise or conversion : show line 3 in the form Employee Stock Option (right to buy) | −1,600 | 69,466 | D |
Loading xslF345X03/doc4.xml…